Journal of Liver: Disease & TransplantationISSN: 2325-9612

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Hepatitis C: Success, but at a High Cost of Cure

Hepatitis C: Success, but at a High Cost of Cure

Hepatitis C is a chronic infection that afflicts approximately 170 million people worldwide with annual mortality of 350,000. There are approximately 15,000 deaths annually in the US. The US Food and Drug Administration (FDA) has recently approved the combination medication Ledipasvir/Sofosbuvir under the trade name of Harvoni with dramatically higher cure rates with fewer side effects than the interferon and ribavirin based regimens. The breakthrough treatment comes at a price that may place it out of reach for all but the wealthiest or best-insured patients.

Special Features

Full Text

View

Track Your Manuscript

Recommended Conferences

Share This Page

Media Partners

Associations